"It would seem that the drug is working in tandem with Zenith."

Yes, ZEN-3694 in combination with enzalutamide is showing promise in the early Phase 1 trial results. 

"I view their results more favourably than Rvx just my view which may be incorrect."

Everyone is entitled to an opinion. I'm not taking sides here, but just to point out.....

Apabetalone/RVX-208:

1) Has been in clinical trials for ~10 years and is now in Phase 3

2) Has revealed no significant safety concerns in patients dosed for up to 2 years

3) Has been used in over 1500 patients

4) Shows promise in reducing major adverse cardiac events in post-hoc analyses of Phase 2 trials

5) Seems to work well in tandem with statins

6) Is the only bromodomain-2 selective BET bromodomain inhibitor in clinical trials

ZEN-3694:

1) Has been in clinical trials for ~1.5 years and is only in Phase 1

2) No safety/toxicity data revealed yet, but others in pan-BET inhibitor area have elicited some concerning side effects. Jury still out as to whether ZEN-3694 has these same common side effects.

3) Has been used in less than 100 patients

4) Shows promise early mCRPC results, though no clinical trials with ZEN-3694 have completed yet. Early clinical results based on just a few patients.

5) Seems to work well in tandem with enzalutamide

6) Is one of many pan-BET inhibitors being tested for various oncology indications

I'm not sure why you are trying to choose sides and directly compare Zenith to Resverlogix or ZEN-3694 to apabetalone/RVX-208. Why not be confident and excited about both?

BearDownAZ